BIONTECH

Annual General Meeting 2022

June 1st, 2022

HARNESSING THE POWER OF THE IMMUNE SYSTEM TO DEVELOP NOVEL THERAPIES

English Convenience Translation: German language is decisive.

MANAGEMENT REPORT

AGENDA NO. 1

01

OPERATING DEVELOPMENT 2021 / Q1 2022 AND OPERATING OUTLOOK 2022

Prof. Dr. Ugur Sahin, CEO & Founder

02

FINANCIAL DEVELOPMENT 2021 / Q1 2022 AND FINANCIAL OUTLOOK 2022

Jens Holstein, CFO

BIONTECH

OPERATING DEVELOPMENT 2021 & Q1 2022 AND OPERATING OUTLOOK 2022

Prof. Ugur Sahin, M.D.
CEO and Founder

This Slide Presentation Includes Forward-looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected revenues and net profit related to sales of our COVID-19 vaccine, referred to as COMIRNATY® where approved for use under full or conditional marketing authorization, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners; our pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to our other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the rate and degree of market acceptance of our COVID-19 vaccine and, if approved, our investigational medicines; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; our collaboration with Pfizer to develop and market a COVID-19 vaccine (including a potential booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; our ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines; the impact of the COVID-19 pandemic on our development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us; our ability to progress our Malaria, Tuberculosis and HIV programs, including timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the nature and duration of support from the World Health Organization, the European Commission and other organizations with establishing infrastructure; the development of sustainable vaccine production and supply solutions on the African continent and the nature and feasibility of these solutions; our estimates of research and development revenues, commercial revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, shares outstanding; our ability and that of our collaborators to commercialize and market our product candidates, if approved, including our COVID-19 vaccine; our ability to manage our development and expansion; regulatory developments in the United States and foreign countries; our ability to effectively scale our production capabilities and manufacture our products, including our target COVID-19 vaccine production levels, and our product candidates; and other factors not known to us at this time. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading “Risk Factors” in this presentation for the three months ended March 31, 2022 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof.

Safety Information

COMIRNATY® ▼(the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorization (CMA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from 5 years of age. The vaccine is administered as a primary course of 2 doses, 3 weeks apart. In addition, the CMA has been expanded to include a booster dose (third dose) at least 6 months after the second dose in individuals 12 years of age and older. For immunocompromised individuals, a third primary course dose may be given at least 28 days after the second dose. The European Medicines Agency's (EMA's) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available.

IMPORTANT SAFETY INFORMATION:

- Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
- There is an increased risk of myocarditis and pericarditis following vaccination with Comirnaty. These conditions can develop within just a few days after vaccination, and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general.
- Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions (e.g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, paraesthesia, hypoaesthesia and sweating) may occur in association with the vaccination process itself. Stress-related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting.
- Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
- As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
- The efficacy and safety of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of Comirnaty may be lower in immunocompromised individuals. As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine.
- In clinical studies, adverse reactions in participants 16 years of age and older were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.
- The overall safety profile of COMIRNATY® in participants 5 to 15 years of age was similar to that seen in participants 16 years of age and older.
- The most frequent adverse reactions in children 5 to 11 years of age were injection site pain (>80%), fatigue (>50%), headache (>30%), injection site redness and swelling (>20%), myalgia and chills (>10%).
- The most frequent adverse reactions in clinical trial participants 12 to 15 years of age were injection site pain (> 90%), fatigue and headache (> 70%), myalgia and chills (> 40%), arthralgia and pyrexia (> 20%).
- A large amount of observational data from pregnant women vaccinated with Comirnaty during the second and third trimester have not shown an increase in adverse pregnancy outcomes. While data on pregnancy outcomes following vaccination during the first trimester are presently limited, no increased risk for miscarriage has been seen. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development. Comirnaty can be used during pregnancy.
- No effects on the breast fed newborn/infant are anticipated since the systemic exposure of breast feeding woman to Comirnaty is negligible. Observational data from women who were breast feeding after vaccination have not shown a risk for adverse effects in breast fed newborns/infants. Comirnaty can be used during breast feeding. Interactions with other medicinal products or concomitant administration of COMIRNATY® with other vaccines has not been studied.
- For complete information on the safety of COMIRNATY® always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website.

The black equilateral triangle ▼ denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to EudraVigilance or directly to BioNTech using email medinfo@biontech.de, telephone +49 6131 9084 0, or via the website www.biontech.de

Safety Information

AUTHORIZED USE IN THE U.S.

COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. It is also authorized under EUA to provide a 2-dose primary series to individuals 5 years of age and older, a third primary series dose to individuals 5 years of age and older who have been determined to have certain kinds of immunocompromise, a single booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY®, a single booster dose to individuals 18 years of age and older who have completed primary vaccination with a different authorized COVID-19 vaccine, a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized COVID-19 vaccine; and a second booster dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise and who have received a first booster dose of any authorized COVID-19 vaccine.

The booster schedule is based on the labeling information of the vaccine used for the primary series.

IMPORTANT SAFETY INFORMATION

Individuals should not get the vaccine if they:

- had a severe allergic reaction after a previous dose of this vaccine
- had a severe allergic reaction to any ingredient of this vaccine

Individuals should tell the vaccination provider about all of their medical conditions, including if they:

- have any allergies
- have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects the immune system
- are pregnant, plan to become pregnant, or are breastfeeding
- have received another COVID-19 vaccine
- have ever fainted in association with an injection

The vaccine may not protect everyone. Side effects reported with the vaccine include:

- There is a remote chance that the vaccine could cause a severe allergic reaction
  - A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination
  - Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness
  - If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital
- Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine, more commonly in males under 40 years of age than among females and older males. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:
  - chest pain
  - shortness of breath
  - feelings of having a fast-beating, fluttering, or pounding heart
- Additional side effects that have been reported with the vaccine include:
  - severe allergic reactions; non-severe allergic reactions such as injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); decreased appetite; diarrhea; vomiting; arm pain; and fainting in association with injection of the vaccine
- These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The possible side effects of the vaccine are still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away

Data on administration of this vaccine at the same time as other vaccines have not yet been submitted to FDA. Individuals considering receiving this vaccine with other vaccines should discuss their options with their healthcare provider.

Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://www.vaers.hhs.gov or call 1-800- 822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.

Pfizer BIONTECH

OUR VISION

Harnessing the power of the immune system to develop novel therapies against cancer, infectious diseases and other severe diseases.

BIONTECH

BioNTech Today | A 21st Century Immunotherapy Powerhouse

2021: Key Highlights of Progress Towards Vision

COMIRNATY - GLOBAL LEADERSHIP

~2.6 bn
doses delivered in 2021[1]

to

>165
Countries & territories[1]

>1 bn
to low- and middle-income countries[1]

DROVE ADVANCEMENT IN ONCOLOGY

Five randomized phase 2 trials

Four new platforms entered the clinic (FIH)

Three strategic M&As to complement existing technologies

EXPANDED GLOBAL ORGANIZATION

3,000+ team members
Increased footprint with new offices in U.S., Europe and Asia

STRONG FINANCIAL PERFORMANCE

€19.0 Bn
Total 2021 Revenues[2]

€39.63
Diluted EPS[2]

[1] As of end 2021; [2] Estimated figures based on preliminary data shared between Pfizer and BioNTech as further described in our Annual Report on Form 20-F for the year ending December 31, 2021; FIH: First in humans

2021: A Year of Historic Impact

First ever approved mRNA therapy[1]

Fastest vaccine development in medical history

One of the **most successful** pharmaceutical launches in history[2]

>1 bn individuals vaccinated in 2021

COMIRNATY market share[3]: USA: ~74%; EU: ~80%

Millions of cases of severe illness or death likely averted[4]

Trillions of dollars of global economic impact[5]

[1]Approved for emergency use/temporary supply or Conditional Marketing Authorization in more than 90 countries worldwide including the U.S. and EU, December 2021
[2] Doses shipped in first year after launch; [3] As of mid December 2021; [4] Eric C. Schneider et al., The U.S. COVID-19 Vaccination Program at One Year: How Many Deaths and Hospitalizations Were Averted? (Commonwealth Fund, December 2021); European Centre for Disease Prevention and Control; [5]Statista

2021: A Year of Transformation & Progress

Expansion of oncology pipeline	Nine oncology clinical trials started; clinical results from six phase 1 studies
Expansion of R&D and production teams	Increased R&D and production teams to >2,000 professionals[1]
Production capacity	Expansion of commercial scale mRNA production and addition of US cell therapy manufacturing facility
Global presence	Established offices in Singapore, China and Turkey
Commercial infrastructure	Deployed commercial team in Germany

[1] As of December 31, 2021, BioNTech Group; R&D: Research & development

Diversity – Important Success Factor



Seven sites
in Germany

> 3,000 employees[1]
> 60 nationalities
> 1,200 new colleagues

Female employees in the total workforce

51%

Females in top management positions

43 %

Twelve subsidiaries
worldwide

Cambridge, USA
Gaithersburg, USA
Istanbul,Turkey
Singapore
Shanghai, China
Reading, UK
Vienna, Austria

[1] As of December 31, 2021, BioNTech Group

Global Social Responsibility at Our Core

Democratize Access to Novel Medicines

COVID-19 vaccine pledge to COVAX and the world

- 2+ bn doses to low- and middle-income countries by end of 2022

Development of new drugs for diseases with high unmet medical need in low-income countries

- Malaria
- Tuberculosis
- HIV

Start to establish mRNA production in Africa to ensure local vaccine supply; planned for mid-2022

Modular "BioNTainer" mRNA production facilities as technological solution to democratize access to novel medicines

Environmental & Climate Protection

Climate targets under SBTi

- Scope 1 & 2:
  absolute emission reduction of 42% by 2030[1]

Responsible Governance

Practice good corporate governance and social and societal responsibility

- Signed UN Global Compact[2]

Attractive Employer

Recruitment of qualified employees

- Specialists for scientific innovation and support of global growth

SBTi, Science Based Targets initiative (in line with Paris agreement)
[1] base year: 2021; [2] encompasses adhering to ten principles on human rights, the environment and anti-corruption

BIONTECH

MULTI-PLATFORM STRATEGY

BIONTECH

Multi-platform Strategy: Toolbox for Innovation



*mRNA encoded cancer-targeting antibodies and cytokines

DIVERSIFIED PRODUCT PIPELINE

Waves of Innovation Propel Us Toward Our Vision

POTENTIAL FOR MULTIPLE PRODUCT LAUNCHES IN NEXT THREE TO FIVE YEARS

Indication:	COVID-19	Oncology	Infectious diseases	New disease areas
	One marketed vaccine	16 PROGRAMS IN 20 CLINICAL TRIALS FIVE RANDOMIZED PHASE 2 TRIALS	ONE PHASE 1 PROGRAM 10+ PRECLINICAL PROGRAMS	LEAD CANDIDATE SELECTION Autoimmune diseases, Regenerative medicine, Cardiovascular diseases
	Driving transformation TODAY	Near- and mid-term		Long-term

Once in a generation opportunity to transform medicine

BIONTECH

2022: Success Through Further Development of the COVID-19 Vaccine

2022: Strong market position

- **~3.4 bn** doses shipped to **>175 countries and regions** since product launch[1]
- Order book 2022[1]: **~2.4 bn doses**

Expansion of global market position

- ✓ Product optimization: new formulation
- ✓ Pediatric label expansion for different age groups
- ✓ Evaluation and approval of booster
- ✓ Label expansion to additional at-risk groups
- ✓ Future pandemic preparedness
  - Monitoring of emerging variants
  - Rapid data-guided vaccine adaptation
- ✓ Development of variant-adapted and next-generation vaccines

[1] As of end of April 2022
Distribution of COVID-10 vaccine in collaboration with Pfizer

BIONTECH

COVID-19 Vaccine: Staying Ahead of the Virus with Innovation

	Goal	R&D Strategy
Landscape Research	Understanding dynamics of SARS-CoV-2 immunity	Research program to study immune profile of anti-SARS-CoV-2 after vaccination, boosters and breakthrough infections
Product Research	COVID-19 follow-on and next-generation vaccines	 COMIRNATY · **Omicron adapted** · **Mono-/ multi-valent** · **T-cell en-hancement** · **Pan-Coronavirus coverage**
Clinical Product Development	Clinical studies to evaluate the safety, tolerability, and immunogenicity of variant-adapted vaccines	Comprehensive clinical program to evaluate variant-adapted and next-generation COVID-19 vaccines • Clinical evaluation of mono- and bivalent and variant-adapted vaccines • New clinical results to be discussed with regulatory authorities

Infectious Diseases: Important Area of Growth

Addressing a high medical need

- Tackling **global health problems** (malaria, tuberculosis, and HIV)
- **Combating** diseases for which there is not yet a prophylactic vaccine or therapy

Wide range of innovative technologies

- Applying **new technologies**, including
  - mRNA vaccines
  - trans-amplifying mRNA
  - Ribologicals
  - synthetic anti-bacterial agents (synthetic lysins)
- AI methods to **accelerate** the development of new vaccines and therapies

AI: Artificial intelligence; Riibologics: *mRNA encoded cancer-targeting antibodies and cytokines

Infectious Disease Pipeline: Expect to Start Four Clinical Trials

	Platform	Product candidate	Preclinical	Phase 1	Phase 2	Phase 3	Market	Milestones 2022
3 mRNA vaccines partnered with Pfizer	COVID-19 Vaccine[1]	BNT162b2						Several updates on data
	Influenza[1]	BNT161						Data update: 2022
	Shingles[1]	-						Start Phase 1
10+ additional vaccine programs	Malaria	-						Start Phase 1
	Tuberculosis[2]	BNT164						Start Phase 1
	HSV 2	-						Start Phase 1
	HIV[2]	-						
	Additional mRNA-vaccine programs[3]	-						
	Precision antibacterials	-						

Ongoing clinical trial Planned clinical trial

[1] Partnered with Pfizer. 2 Partnered with Bill & Melinda Gates Foundation. BioNTech holds worldwide distribution rights except developing countries where Bill & Melinda Gates Foundationholds distribution rights;
[3] University of Pennsylvania collaboration

BIONTECH

Oncology: New Precision Therapies with Scaling Potential

Our innovative approach

- Development of **precise** immuno-oncology therapies
- **Individualized** therapeutic approaches
- **Scale of platforms** across tumor indications
- **Combination** of different immuno-oncology mode of action

Overcoming therapeutic limitatons in the treatment of solid tumors

A future model for immuno-oncology



BIONTECH

Oncology Pipeline: Significant Progress and Expansion

Drug class	Plattform	Product candidate	Indication (targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Milestones
mRNA	**FixVac** (fixed combination of shared cancer antigens)	BNT111	Advanced melanoma					
		BNT112	Prostate cancer					
		BNT113	HPV16+ head and neck cancer					
		BNT115[1]	Ovarian cancer[1]					
		BNT116	NSCLC					Start Phase 1/2
	iNeST (patient specific cancer antigen immune therapy)	Autogene cevumeran (BNT122)[2]	1L melanoma					Data:H2 2022
			Adjuvant colorectal cancer					
			Solid tumors					
	Intratumoral Immunotherapy	SAR441000 (BNT131)[3]	Solid tumors (IL-12sc, IL15-sushi, GM-CSF, IFNα)					
	RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple solid tumors (CLDN18.2)					FPD Jan 2022
		BNT142	Multiple solid tumors (CD3+CLDN6)					Start Phase 1/2
	RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple solid tumors (optimized IL-2)					
		BNT152, BNT153	Multiple solid tumors (IL-7, IL-2)					
Cell Therapies	**CAR-T Cells + Carvac**	BNT211	Multiple solid tumors (CLDN6)					Data: H2 2022:
		BNT212	Pancreatic, other cancers (CLDN18.2)					
	Neoantigen-based T cells	BNT221 (NEO-PTC-01)	Multiple solid tumors					
	TCR engineered T cells	To be selected	All tumors					
Antibodies	**Next-Gen CP Immunomodulators**	GEN1046 (BNT311)[4]	Metastatic NSCLC (PD-L1x4-1BB)					
			Multiple solid tumors (PD-L1x4-1BB)					
		GEN1042 (BNT312)[4]	Multiple solid tumors (CD40x4-1BB)					
	Targeted Cancer Antibodies	BNT321 (MVT-5873)	Pancreatic cancer (sLea)					
SMIM	**Toll-Like Receptor Binding**	BNT411	Solid tumors (TLR7)					

Phase 1 Phase 2 Planned Phase 1

[1] BNT115 is currently being studied in an investigator-initiated Phase 1 trial [2] Collaboration with Genentech [3] Collaboration with Sanofi [4] Collaboration with Genmab
SMIM, Small Molecule Immunomodulators

BIONTECH

Oncology Programs in Phase 2

Platform	FixVac Off-the-shelf mRNA vaccine		iNeST Individualized mRNA immunotherapy		Bispecific Next-generation immunotherapy
Program	**BNT111** R/R Melanoma	**BNT113** HPV16+ HNSCC	**BNT122** Autogene cevumeran[1] 1L Melanoma	**BNT122** Autogene cevumeran[1] Adjuvant colorectal cancer	**BNT311[2]** R/R NSCLC
How	• Encodes 4 tumor-associated antigens U.S. Fast Track Designation and Orphan Drug Designation	• Encodes HPV16 oncoproteins	• Targets 20 neo-antigens unique to each patient • Data update expected 2H 2022	• Targets 20 neo-antigens unique to each patient	• Conditional 4-1BB co-stimulation while blocking PD(L)1 axis
Why	Potential to improve outcomes in combo with anti-PD1	Potential for synergistic anti-tumor effect in combination with anti-PD1	Trial success may unlock 1L use of iNeST as combination therapy with anti-PD(L)1 in anti-PD1-naive advanced cancers	Potential to address residual cancer cells that remain – focus on recurrence free survival	Enhances T-cell and NK cell function and targets them to tumor lesions

R/R, refractory/relapsed; HPV16+, human papilloma virus type 16 positive; HNSCC, head and neck squamous cell carcinoma; NK cell, natural killer cell; CPI, checkpoint inhibitor
[1] Collaboration with Genentech, [2] Collaboration with Genmab.

OUTLOOK 2022

BIONTECH

2022 Strategic Priorities

Continue COVID-19 Vaccine Leadership

- Label & geographic expansion
- Next-generation vaccines
- Innovations for pandemic preparedness

Execute in Oncology

- First randomized Phase 2 readout
- Prepare for registrational trials
- Additional data for CAR-T cell therapy against solid tumors

Expand in Infectious Disease

- Initiate 4 FIH vaccine trials:
- 10+ additional mRNA vaccine programs
- Precision antibacterials

Advance into New Therapeutic Areas

- Autoimmune disease
- Regenerative medicine
- Cardiovascular disease

Invest in Foundation to Enable Accelerated Innovation and Expansion

Digital & AI Capabilities | Technologies | Development Team | Manufacturing | Global Footprint

FIH, first–in-human;; AI, artificial intelligence

FINANCIAL DEVELOPMENT 2021 / Q1 2022 AND FINANCIAL OUTLOOK 2022

Jens Holstein
CFO

Key Highlights of the 2021 Financial Year

Total Revenues[1]

€ 19.0 bn

Operating Result

€ 15.3 bn

Diluted EPS

€ 39.63

Cash + Cash Deposits and Trade Receivables

€ 2.1 bn[2] + € 12.4 bn

[1] BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual and Quarterly Reports. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.

[2] Includes cash and cash equivalents (€1.7 bn) and cash deposits with an original term of six months which are presented as other financial assets (€0.4 bn).

BIONTECH

Key Highlights of the 2021 Financial Year (2)

COVID-19 Vaccine Commercial Revenues[1]: € 18.8 bn

- Share of gross profit and sales milestones from COVID-19 vaccine sales in the Pfizer and Fosun Pharma territory (100% gross margin)
- Direct COVID-19 vaccine sales to customers in BioNTech's territory
- COVID-19 sales to collaboration partners of products manufactured by BioNTech

Doses: ~2.6 bn delivered

Low- and Middle-Income Countries
~40%

High-Income Countries
~60%

Revenues and Margins exceeded Expectations

[1] BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual and Quarterly Reports. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.

Key Highlights of the 2021 Financial Year (3)

Cash

€ 1.7 bn

Cash and cash equivalents as of December 31, 2021

Cash Deposits[1]

€ 0.4 bn

Cash deposits as of December 31, 2021

Trade Receivables

€ 12.4 bn

Trade receivables as of December 31, 2021

Funds to finance our Growth[2]

1 Cash deposit with an original term of six months are presented as other financial assets.
2 Additional influencing factors (i.e. cash outlays) as well as certain collection risk with trade receivables exist.

BIONTECH

Comparison Guidance to Actuals 2021 Financial Year

	Guidance as of Nov 2021	Actual result FY 2021[1]	Drivers[1]
COVID-19 vaccine revenues	**€ 16 - 17 bn**	**€ 19 bn**	• ~2.6 bn COVID-19 vaccine doses delivered in 2021 vs. up to 2.5 bn doses guided • Higher proportion of doses than estimated delivered to HIC[2]
R&D expenses	**€ 950 - 1,050 m**	**€ 950 m**	• ~40% related to COVID-19 vaccine clinical program
SG&A expenses	**€ 250 - 300 m**	**€ 340 m**	• Increase through organic and inorganic growth of organization
Capital expenditures	**€ 175 - 225 m**	**€ 180 m**	• Investment in infrastructure and COVID-19 vaccine production capacity

[1] Please refer to the Annual Report on Form 20-F for the year ended December 31, 2021, for further details.
[2] HIC, high-income countries

FY 2021 Financial Results – Profit or Loss

(€ in millions, except per share data)[1]	FY 2021	FY 2020
Research & development revenues	102.7	178.8
Commercial revenues[2]	18,874.0	303.5
Total revenues	**18,976.7**	**482.3**
Cost of sales	(2,911.5)	(59.3)
Research and development expenses	(949.2)	(645.0)
Sales and marketing expenses	(50.4)	(14.5)
General and administrative expenses	(285.8)	(94.0)
Other operating income less expenses	504.0	248.1
Operating income / (loss)	**15,283.8**	**(82.4)**
Finance income less expenses	(237.4)	(63.4)
Income taxes	(4,753.9)	161.0
Profit / (loss) for the period	**10,292.5**	**15.2**
Earnings per share		
Basic profit / (loss) for the period per share	42.18	0.06
Diluted profit / (loss) for the period per share	39.63	0.06

1 Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context.
Presentation of the consolidated statements of profit or loss has been condensed.
2 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual and Quarterly Reports. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.

BIONTECH

Key Highlights of the First Quarter of 2022

Total Revenues[1]	Operating Result
€ 6.4 bn	€ 4.8 bn

Diluted EPS	Cash and Trade Receivables
€ 14.24	€ 6.2 bn + € 12.7 bn

1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual and Quarterly Reports. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.

Q1 2022 Financial Results – Profit or Loss

(€ in millions, except per share data)[1]	Q1 2022	Q1 2021
Research & development revenues	12.4	20.9
Commercial revenues[2]	6,362.2	2,027.5
Total revenues	**6,374.6**	**2,048.4**
Cost of sales	(1,294.1)	(233.1)
Research and development expenses	(285.8)	(216.2)
Sales and marketing expenses	(14.3)	(8.7)
General and administrative expenses	(90.8)	(38.9)
Other operating income less expenses	63.1	110.7
Operating income	**4,752.7**	**1,662.2**
Finance income less expenses	265.4	(19.9)
Income taxes	(1,319.3)	(514.2)
Profit for the period	**3,698.8**	**1,128.1**
Earnings per share		
Basic profit for the period per share	15.13	4.64
Diluted profit for the period per share	14.24	4.39

1 Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context.
Presentation of the consolidated statements of profit or loss has been condensed.
2 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual and Quarterly Reports. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.

BIONTECH

2022 Financial Year Guidance

COVID-19 Vaccine Revenues for FY 2022[1]	
Estimated BioNTech COVID-19 vaccine revenues	**€ 13 – 17 bn**
Planned FY 2022 Expenses and Capex[1]	
R&D expenses	**€ 1,400 - 1,500 m**
SG&A expenses	**€ 450 - 550 m**
Capital expenditure	**€ 450 - 550 m**
Estimated FY 2022 Tax Assumptions	
BioNTech Group estimated annual effective income tax rate	**~28%[2]**

[1] Ranges reflect current base case projections and do not include potential effects caused by or driven from additional collaborations or potential M&A transactions.
[2] BioNTech Group estimated annual effective income tax rate decreased from 31.6% (FY 2021) to ~28% (FY 2022) mainly due to decreasing average trade tax rates.

Capital Allocation Framework for the 2022 Financial Year

R&D Activities

Accelerate R&D activities in the years to come

M&A and Business Development

Strengthen technology platforms and digital capabilities by collaborations and potential add-on M&A

Corporate and Infrastructure

Develop global footprint and invest in manufacturing capabilities for key technologies

Return Capital to Shareholders

Share repurchase program of up to $ 1.5 bn over the next two years

Proposal of a special cash dividend of € 2.00 per share, aggregate of ~€ 0.5 bn[1]

1 Based on the ordinary shares outstanding and entitled to dividends as of May 30, 2022 and pending approval by the Annual General Meeting.

Capital Transactions in FY 2021 and during the Period until June 2022

	Fulfillment period	Number of ordinary shares issued	Share of issued share capital[1]	Issuing price	Total issue amount
Use of treasury shares					
At-The-Market-Offering Programm	May 2021	995,890[2]	0.4%	€ 164.29[3]	€ 163.6 m[3]
Total number of treasury shares sold		**995,890**			
Capital increases from authorized or conditional capital with the exclusion of subscription rights					
Pfizer Inc. (authorized capital with simplified exclusion of subscription rights[4])	March 2022	497,727	0.2%	€ 266.63[5]	€ 132.7 m[5]
Ellington Investments Pte. Ltd. (“Temasek”) Mandatory convertible bond (conditional capital)	April 2022 (June 2020[6])	1,744,392	0.7%	€ 57.33[6]	€ 100.0 m[6]
Total number of ordinary shares issued from authorized or conditional capital with exclusion of subscription rights		**2,242,119**			

[1] The "share of issued share capital" ratio is calculated on the basis of the shares issued as of the respective fulfillment period.
[2] Represents use of ordinary shares previously held in treasury.
[3] Average issuing price. The ordinary shares were issued in U.S. dollars. Conversion into Euros is made using the foreign exchange rate as published by the German Central Bank (*Deutsche Bundesbank*) as of the time of the transactions.
[4] Sec.186 para. 3 sent.4 German Stock Corporation Act (*Aktiengesetz*).
[5] The ordinary shares were issued in U.S. dollars; the amounts represent the issue amount agreed in the Investment Agreement. Conversion into Euros is made using the foreign exchange rate as published by the German Central Bank (*Deutsche Bundesbank*) as of the time the issue price was defined. The opening price of the BioNTech ADS on January 3, 2022 (first trading day after the signing of the Management Board resolution on the Investment Agreement) on the Nasdaq Global Select Market was €223.58 (converted into Euros using the foreign exchange rate as published by the German Central Bank (*Deutsche Bundesbank*) for that day). Balance sheet figures differ.
[6] Based on contractual agreements from June 2020.

Share Repurchase Program

- Repurchase American Depositary Shares (ADS) in the amount of up to $ 1.5 bn
- Term of up to two years
- Repurchased ADSs are to be used in whole or in part to satisfy upcoming settlement obligations under share-based payment arrangements
- Start of first tranche worth up to $ 1 bn began May 2, 2022

Period	Number of acquired ADS	Percentage of share capital[1]	Average price (in $)	Volume (in million $)
CW 18-21	917,988	0.4%	151.76	139.3

[1] For the share repurchase, the "share of issued common stock" ratio is calculated based on the shares issued as of April 30, 2021 (248,552,200 ordinary shares).

Outlook 2022 and Beyond

Once in a generation opportunity to transform medicine

Further development of COVID-19 vaccine

Accelerate late-stage oncology programs

Ramp up R&D investment

Pursue complementary acquisitions

Expand global organization

Bring long-term value to patients, shareholders and society

BIONTECH

Thank you.